GlaxoSmithKline fined $3bn for healthcare fraud

This article is about GlaxoSmithKline Company’s drug fraud. The company proposed to pay a fine of three billion dollars after pleading guilty to these charges. This plea however, would have to be approved by the Massachusetts federal court. Apart from the fine, in order to ensure that the company complied with health laws and regulations, officials from the government would monitor its operations. The Company faced allegations that it did follow the US standard of pharmaceuticals’ marketing and development. The allegations included allocating anti depressant Paxil to minors, that is, patients below 18 years. The drug had been recommended for adult use only. It also encouraged the use of Wellbutrin drug on what it had not been approved. This included the use of the drug to treat sexual dysfunction and to cause weight loss.

This information was provided by the investigation department of the US justice. According to the prosecutor, in order to enhance the promotion of the drugs, the company produced a false medical journal and distributed it. It bribed doctors by providing meals, spa treatments and expensive entertainment such as vacations to Hawaii, speaking tours and concert tickets. This promotion led to the increase in sales, by one billion dollars annually. On another charge, the company was accused of refusing to provide safety data to the Food and Drug administration of the United States, regarding the Avandia diabetes drug, since 1990 to 2007. This violated the law of the US. In order to avoid criminal charges, the company pleaded guilty to criminal counts of misdemeanor. An official at the US department of justice expressed this as a warning to other companies on the consequences of breaking the law.

The three billion dollar fine constituted of two billion dollars for civil fines and one-billon dollars for forfeitures and criminal fines. The civil fines included improper promotion of various other drugs such as Zofran and Valtrex. The company’s chief executive officer expressed in a statement that the company was remorse and it would not make such mistakes again. The writer states that, GlaxoSmithKline case is bigger than the Pfizer Inc. case in 2009. The case involved accusations of the promotion of thirteen drugs of the company improperly. It also consisted of bribe to doctors, which included massages and free golf. This was so that they could influence the physicians to prescribe the drugs to patients. The case had been settled on a fine of 2.3 billion dollars.

The US Food and Drug administration finally agreed to retain of the company’s Avandia drug on the market. However, the company was required to pay a charge of 1.57 billion dollars that would cover for the drug, as well as the Paxil drug and the closing of the company’s Puerto Rico factory. Medical researchers had been concerned that the Avandia drug was not safe enough to the extent of increasing the risk of getting heart attack. The permission of the drug to remain in the market was relief to the company, as these settled cases regarding the drug’s liability by users. The charge on Paxil drug on the other hand, apart from the target on minors, research also showed it increased suicide risks. The company also faced accusations on breaking the law through application for new patents. This was in order to prevent other pharmaceutical companies from releasing alternatives of Paxil, which were cheaper.

The 1.57 billion dollar charge also includes the closing of the manufacturing facility of the company’s Cidra. In this, the company agreed to cover the cost incurred by the United States Justice department, in investigating manufacturing problems at the facility. The investigation was due to results found by the US Food and Drug administration, which showed that the facility’s tablets could easily break before consumption, resulting to under dosage of the drug. The money also covered legal claims from thirteen thousand people, who claimed that they had been misinformed about the side effects of Avandia. Three thousand of these claims have not yet been settled. An official of the company stated that the charge showed the company’s efforts in settling its legal cases. He also expressed that in issuing the charge, shareholders’ risk and financial uncertainty would be reduced.

This settlement followed a rise in the company’s shares, by 0.8 percent. The company was allowed to keep the product in the market on the condition that it should provide more information on the label, concerning the risks of using the drug. On this basis, the company advised consumers of the drug to follow the advice of a doctor on the use of the drug. It also stated that it would work with authorities from the United States, in order to help people suffering from diabetes. Due to the fear of side effects caused by the drug, sales decreased from 1.4 billion dollars to 771 million dollars, in 2009. The US Justice Department has been concerned with the increase in costs in working with the government, in the provision of drugs. In this, it is monitoring the operations of biotech and pharmaceutical companies.

Reference

Buchbinder, Sharon B, and Nancy H. Shanks. Introduction to Health Care Management. Sudbury, Mass: Jones and Bartlett Publishers, 2007. Print.

Leap, Terry L. Phantom Billing, Fake Prescriptions, and the High Cost of Medicine: Health Care Fraud and What to Do About It. Ithaca: ILR Press, 2011. Print.

Health Care Fraud. Minneapolis, MN: Minnesota Institute of Legal Education, 2000. Print.

Baumann, Linda A. Health Care Fraud and Abuse: Practical Perspectives. Chicago, Ill.: American Bar Association, Health Law Section, 2002. Print.

Adams, David G. Food and Drug Law and Regulation. Washington, D.C: FDLI, 2008. Print.

Article used

GlaxoSmithKline fined $3bn for healthcare fraud

Pharmaceutical giant pleads guilty to three criminal charges over mis-selling of drugs and withholding of data

GlaxoSmithKline has agreed to plead guilty to misdemeanour criminal charges and pay $3bn to settle what government officials describe as the largest case of healthcare fraud in US history.

The agreement, which still needs court approval, would resolve allegations that the British drug maker broke US laws in the marketing and development of pharmaceuticals. The terms of the settlement were announced in November.

GSK targeted the antidepressant Paxil at patients under age 18 when it was approved only for adults, and promoted the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction, according to a US justice department investigation.

The company went to extreme lengths to promote the drugs, such as distributing a misleading medical journal article and providing doctors with meals and spa treatments that amounted to illegal kickbacks, prosecutors said.

“The sales force bribed physicians to prescribe GSK products using every imaginable form of high-priced entertainment, from Hawaiian vacations [and] paying doctors millions of dollars to go on speaking tours, to tickets to Madonna concerts,” said US attorney Carmin Ortiz.

In a third case, GSK failed to give the US Food and Drug Administration safety data about its diabetes drug Avandia, in violation of US law, prosecutors said.

The misconduct began in the late 1990s and continued, in the case of Avandia’s safety data, through to 2007. GSK agreed to plead guilty to three misdemeanour criminal counts, one each related to the three drugs.

Guilty pleas in cases of alleged corporate misconduct are exceedingly rare, making GSK’s agreement especially unusual.

The agreement to settle the charges “is unprecedented in both size and scope”, said James Cole, the no 2 official at the US justice department. He called the action “historic” and “a clear warning to any company that chooses to break the law”.

The settlement includes $1bn in criminal fines and $2bn in civil fines.

Chief executive officer Andrew Witty said the misconduct originated “in a different era for the company” and would not be tolerated. “I want to express our regret and reiterate that we have learned from the mistakes that were made,” he said in a written statement.

The GSK settlement surpasses what had been the largest criminal case involving a drug maker in US history. In 2009, Pfizer Inc agreed to pay $2.3bn to settle allegations that it improperly marketed 13 drugs.

The cases follow a trend of US authorities cracking down on how pharmaceuticals are sold, in part because of the rising cost of providing drugs through government programmes.